HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BLyS receptor

BLyS - B LYmphocyte Stimulator; receptor for BLyS which is a member of TNF family

Also Known As:

BLyS receptors; receptor, BLyS

Networked: 7 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - Immunologic Receptors: 9
        Cytokine Receptors: 1620
        Tumor Necrosis Factor Receptors: 3685
        BLyS receptor: 7

Experts

1.	Lyu, Mi-Ae: 3 articles (09/2012 - 02/2007)
2.	Rosenblum, Michael G: 3 articles (09/2012 - 02/2007)
3.	Cheung, Lawrence H: 2 articles (09/2012 - 02/2007)
4.	Hittelman, Walter N: 2 articles (09/2012 - 02/2007)
5.	Marks, John W: 2 articles (09/2012 - 02/2007)
6.	Angelopoulou, Maria K: 1 article (01/2014)
7.	Bartzis, Vassiliki: 1 article (01/2014)
8.	Dimou, Maria: 1 article (01/2014)
9.	Kalpadakis, Christina: 1 article (01/2014)
10.	Koulieris, Efstathios: 1 article (01/2014)

Related Diseases

1.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 03/01/2013 - "The study was promoted to probe into the effect of BLyS on the activity of peripheral B lymphocytes mediated by BLyS receptors in patients with systemic lupus erythematosus (SLE). " 03/01/2013 - "The effect of BLyS on the activity of peripheral B lymphocytes mediated by BLyS receptors in patients with systemic lupus erythematosus."
2.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 09/28/2012 - "Bax(345)/BLyS was cytotoxic to a panel of diffuse large B cell lymphoma and mantle cell lymphoma lines expressing the BLyS receptors. " 02/01/2007 - "Three mantle cell lymphoma (MCL) cell lines (JeKo-1, Mino, and SP53) and two diffuse large B-cell lymphoma (DLBCL) cell lines (SUDHL-6 and OCI-Ly3) expressing all three distinct BLyS receptors were found to be the most sensitive to the fusion toxin (IC(50) = 2-5 pmol/L and 0.001-5 nmol/L for MCL and DLBCL, respectively). "
3.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 09/28/2012 - "Bax(345)/BLyS was cytotoxic to a panel of diffuse large B cell lymphoma and mantle cell lymphoma lines expressing the BLyS receptors. " 02/01/2007 - "Three mantle cell lymphoma (MCL) cell lines (JeKo-1, Mino, and SP53) and two diffuse large B-cell lymphoma (DLBCL) cell lines (SUDHL-6 and OCI-Ly3) expressing all three distinct BLyS receptors were found to be the most sensitive to the fusion toxin (IC(50) = 2-5 pmol/L and 0.001-5 nmol/L for MCL and DLBCL, respectively). "
4.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/01/2014 - "Serum soluble TACI, a BLyS receptor, is a powerful prognostic marker of outcome in chronic lymphocytic leukemia." 03/15/2007 - "Chronic lymphocytic leukemia (CLL) is a B-cell disease and CLL lymphocytes express BLyS receptors. "
5.	Neoplasms (Cancer) 02/01/2002 - "We have studied the tumor cell expression of the BLyS-Receptor (BLyS-R) and the serum BLyS protein levels in patients with different types of non-Hodgkin's lymphomas (NHL). " 02/01/2007 - "Our results suggest that BLyS has the potential to serve as an excellent targeting ligand for the specific delivery of cytotoxic molecules to neoplastic B cells expressing the BLyS receptors, and that the rGel/BLyS fusion toxin may be an excellent candidate for the treatment of B-cell malignancies especially MCL and DLBCL."

Related Drugs and Biologics

1.	B-Cell Activating Factor
2.	Ligands
3.	rGel-BLyS fusion toxin